Document Detail

Acute and severe acne in a patient treated with bevacizumab.
MedLine Citation:
PMID:  23432695     Owner:  NLM     Status:  MEDLINE    
BACKGROUND:   Bevacizumab is a recombinant, humanized monoclonal antibody against vascular endothelial growth factor (VEGF) that inhibits angiogenesis. Bevacizumab is typically well tolerated; its major side effects include hypertension, proteinuria, bleeding, gastrointestinal perforation, and arterial thrombotic events, among others. Cutaneous side effects associated with the use of bevacizumab are rare and involve mainly itching and exfoliative dermatitis. Nonspecific skin rash and acneiform eruptions have recently been described in patients following infusion of bevacizumab.
METHODS:   Findings in a 52-year-old patient with stage IV lung cancer with brain metastasis, who developed severe, acute, and persistent acne after intravenous (IV) infusion of bevacizumab, are examined.
RESULTS:   The cutaneous eruption was classified as true acne rather than as an acneiform eruption because all cutaneous lesions of acne, namely comedones, inflammatory papules, and pustules, were present.
CONCLUSIONS:   To the authors' knowledge, this is the first report of an association between acne and IV administration of bevacizumab.
Ana María Molina-Ruiz; Manuel Domine; Luis Requena
Related Documents :
24323715 - Cerebral lactate correlates with early onset pneumonia after aneurysmal sah.
23432695 - Acute and severe acne in a patient treated with bevacizumab.
23018355 - Soluble trail as a marker of efficacy of allergen-specific immunotherapy in patients wi...
24949575 - Impact of family support on psychiatric disorders and seizure control in patients with ...
15375305 - Diffusion-weighted mri in 300 patients presenting late with subacute transient ischemic...
25270625 - Hemorrhagic stroke and cerebral paragonimiasis.
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2013-02-22
Journal Detail:
Title:  International journal of dermatology     Volume:  52     ISSN:  1365-4632     ISO Abbreviation:  Int. J. Dermatol.     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-03-15     Completed Date:  2013-11-15     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  0243704     Medline TA:  Int J Dermatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  486-90     Citation Subset:  IM    
Copyright Information:
© 2013 The International Society of Dermatology.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acne Vulgaris / chemically induced*,  drug therapy,  pathology
Acute Disease
Adenocarcinoma / drug therapy*,  secondary
Angiogenesis Inhibitors / adverse effects*,  therapeutic use
Antibodies, Monoclonal, Humanized / adverse effects*,  therapeutic use
Brain Neoplasms / drug therapy*,  secondary
Drug Eruptions / etiology*
Lung Neoplasms / drug therapy*,  pathology
Middle Aged
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prevalence of viruses in stool of premature neonates at a neonatal intensive care unit.
Next Document:  Relaxin-3 innervation of the intergeniculate leaflet of the rat thalamus - neuronal tract-tracing an...